Tyramine ( DrugBank: Tyramine )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	2

6. パーキンソン病

---

臨床試験数 : 2,298 /  薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2006-005140-89-NL (EUCTR)	11/12/2006	01/12/2006	A PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY SUBJECTS - Tyramine challenge study	A PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY SUBJECTS - Tyramine challenge study	This postmarketing Phase I study is performed in healthy volunteers. The IMP rasagiline 1mg is indicated for the treatment of Parkinson's Disease (PD). MedDRA version: 9.1;Level: PT;Classification code 10061536	Trade Name: Selegiline HCl 5 PCH Trade Name: Nardil Product Name: Rasagiline 1mg tablet Product Code: TVP-1012 INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesilate Product Name: Rasagiline 2 mg tablet Product Code: TVP-1012 INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesilate	TEVA Pharmaceuticals Industries Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	160	Phase 1	Netherlands
2	NCT00203125 (ClinicalTrials.gov)	October 2000	13/9/2005	A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.	Sub-study to Evaluate the Effect of An Oral Dose of Tyramine in Subjects Completing 26 Weeks of Participation in PRESTO (TVP-1012/133)	Parkinson's Disease	Drug: rasagiline mesylate;Other: tyramine	Teva Pharmaceutical Industries	NULL	Completed	N/A	N/A	Both	55	Phase 3	United States